Helius Medical Technologies, Inc. reported significant financial results for the first quarter of 2026, revealing a total revenue of $3.6 million, a substantial increase from just $49,000 in the same period last year. The revenue growth was primarily driven by $3.4 million in staking revenue, reflecting the company's strategic pivot towards digital asset management and staking of Solana tokens (SOL). However, the company also faced considerable challenges, incurring a net loss of $99.8 million, compared to a loss of $3.8 million in the first quarter of 2025. This dramatic increase in losses was largely attributed to unrealized losses on digital assets and related investments, totaling $89.2 million.
The company's operational expenses surged to $103.1 million in the first quarter of 2026, up from $3.9 million in the prior year. This increase was driven by higher general and administrative costs, which rose by $1.3 million due to increased professional fees, trading advisory costs, and insurance expenses. Additionally, the company recorded realized losses of $7.0 million on digital assets, further impacting its financial performance. As of March 31, 2026, Helius reported total assets of $200.7 million, a decrease from $303.9 million at the end of 2025, primarily due to the decline in the value of its digital asset holdings.
In terms of strategic developments, Helius has made notable moves, including the sale of its Portable Neuromodulation Stimulator (PoNS) business for an upfront payment of $5 million, with potential earnout payments of up to $20 million based on future revenues. The company also announced a registered direct offering of 3,076,922 shares of Class A common stock at $2.60 per share, which is expected to generate approximately $7.9 million in net proceeds. Furthermore, Helius has initiated a stock repurchase program, having repurchased 1.6 million shares at an average cost of $2.20 per share.
Operationally, Helius has concentrated its digital asset holdings in SOL, which represented 85.8% of its total assets as of March 31, 2026. The company held approximately 2.3 million SOL tokens, valued at $193.8 million based on a market price of $83.12 per token. The volatility of SOL's price remains a critical factor for Helius, as fluctuations can significantly impact its financial results. The company has indicated that it expects its current liquidity and financial resources to be sufficient to meet its operational needs through at least May 2027, contingent on its ability to liquidate digital assets as necessary.
Looking ahead, Helius remains focused on maximizing the value of its digital asset treasury strategy while navigating the challenges posed by market volatility. The company is committed to leveraging its digital assets for staking and other opportunities within the Solana ecosystem, aiming to enhance its financial performance and operational growth in the coming quarters.
About HELIUS MEDICAL TECHNOLOGIES, INC.
Helius Medical Technologies specializes in neurotechnology, developing non-invasive devices like the PoNS Stimulator to treat neurological conditions such as multiple sclerosis, traumatic brain injury, and stroke. The company's core product delivers mild electrical stimulation to promote neuroplasticity and improve gait and balance. Operating globally, Helius partners with healthcare providers, regulators, and payers to advance neuromodulation therapies for neurological wellness.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.